UY29454A1 - Derivados novedosos de 7-amino-(1,3) tiazol(4,5-d) pirimidina 5-sustituidos - Google Patents
Derivados novedosos de 7-amino-(1,3) tiazol(4,5-d) pirimidina 5-sustituidosInfo
- Publication number
- UY29454A1 UY29454A1 UY29454A UY29454A UY29454A1 UY 29454 A1 UY29454 A1 UY 29454A1 UY 29454 A UY29454 A UY 29454A UY 29454 A UY29454 A UY 29454A UY 29454 A1 UY29454 A1 UY 29454A1
- Authority
- UY
- Uruguay
- Prior art keywords
- amino
- pyrimidine
- disease
- derivatives
- tiazol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Nuevos derivados 5-sustituidos de 7-amino-(1,3) tiazol (4,5-d) pirimidina de fórmula (I)en los que R1, R2, R3, R4 u R5 son como se define en la memoria descriptiva, y sales farmacéuticamente aceptables de los mismos, procesos para su preparación, composiciones farmacéuticas que los comprenden y aplicaciones. Los compuestos de fórmula (I) son antagonistas de receptor CX3CR1 y son así particularmente útiles para tratamiento o profilaxis de trastornos neurodegenerativos, enfermedad desmielizante, trastornos ateroscleróticos cardio y cerebrovasculares, enfermedad arterial periferal, arthritis reumatoide, enfermedades pulmonares como COPD/enfermedad pulmonaria obstructiva crónica/, asma o dolor.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0500767 | 2005-04-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY29454A1 true UY29454A1 (es) | 2006-11-30 |
Family
ID=37073739
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY29454A UY29454A1 (es) | 2005-04-06 | 2006-04-04 | Derivados novedosos de 7-amino-(1,3) tiazol(4,5-d) pirimidina 5-sustituidos |
Country Status (31)
Country | Link |
---|---|
US (2) | US7947693B2 (es) |
EP (1) | EP1869056B1 (es) |
JP (1) | JP5165553B2 (es) |
KR (1) | KR101335055B1 (es) |
CN (1) | CN101193897B (es) |
AR (1) | AR055890A1 (es) |
AT (1) | ATE487727T1 (es) |
AU (1) | AU2006231836B2 (es) |
BR (1) | BRPI0609738A2 (es) |
CA (1) | CA2604017C (es) |
CY (1) | CY1111316T1 (es) |
DE (1) | DE602006018124D1 (es) |
DK (1) | DK1869056T3 (es) |
ES (1) | ES2354450T3 (es) |
HK (1) | HK1118556A1 (es) |
HR (1) | HRP20110047T1 (es) |
IL (1) | IL185912A0 (es) |
MX (1) | MX2007012060A (es) |
NO (1) | NO20075603L (es) |
NZ (1) | NZ561460A (es) |
PL (1) | PL1869056T3 (es) |
PT (1) | PT1869056E (es) |
RS (1) | RS51581B (es) |
RU (1) | RU2419623C2 (es) |
SA (1) | SA06270072B1 (es) |
SI (1) | SI1869056T1 (es) |
TW (1) | TW200714605A (es) |
UA (1) | UA90707C2 (es) |
UY (1) | UY29454A1 (es) |
WO (1) | WO2006107258A1 (es) |
ZA (1) | ZA200708187B (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2641815T3 (es) | 2004-10-29 | 2017-11-14 | Eisai R&D Management Co., Ltd. | Tratamiento para enfermedades inflamatorias |
AR053347A1 (es) | 2005-04-06 | 2007-05-02 | Astrazeneca Ab | Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos |
TW200820973A (en) | 2006-09-29 | 2008-05-16 | Astrazeneca Ab | Novel compounds 480 |
AU2007300749B2 (en) * | 2006-09-29 | 2011-08-25 | Astrazeneca Ab | Novel 5,7-disubstituted [1, 3] thiazolo [4, 5] pyrimidin-2 (3H)-amine derivatives and their use in therapy |
AU2009221063B2 (en) | 2008-03-07 | 2013-03-21 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, and CX3CR1 |
US8461194B2 (en) | 2008-03-07 | 2013-06-11 | Aziende Chimiche Riunite Angelini Francesco A. C. R. A. F. S. P. A. | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and P40 |
LT2254869T (lt) | 2008-03-07 | 2017-08-10 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Nauji 1-benzil-3-hidroksimetilindazolo dariniai ir jų panaudojimas gydyme ligų, susijusių su cx3cr1 ir p40 raiška |
AR076601A1 (es) | 2009-05-21 | 2011-06-22 | Chlorion Pharma Inc | Pirimidinas como agentes terapeuticos |
JO3437B1 (ar) | 2009-10-30 | 2019-10-20 | Esai R & D Man Co Ltd | أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها |
US8435993B2 (en) | 2010-12-07 | 2013-05-07 | Philadelphia Health And Education Corporation | Methods of inhibiting metastasis from cancer |
US8476301B2 (en) | 2011-09-13 | 2013-07-02 | Eisai R&D Management Co., Ltd. | Pyrrolidin-3-ylacetic acid derivative |
JO3082B1 (ar) | 2011-09-13 | 2017-03-15 | Eisai R&D Man Co Ltd | مشتق بيروليدين-3- يل حمض خليك |
JP5872105B2 (ja) | 2013-03-12 | 2016-03-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピロリジン−3−イル酢酸誘導体の塩およびその結晶 |
WO2015048281A1 (en) * | 2013-09-27 | 2015-04-02 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
WO2016200939A1 (en) * | 2015-06-08 | 2016-12-15 | The Johns Hopkins University | Radiofluorinated 7-amino-5-thio-thiazolo[4,5-d]pyrimidines for imaging fractalkine receptor (cx3cr1) |
US11267817B2 (en) | 2017-05-02 | 2022-03-08 | Drexel University | Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists |
GB201807898D0 (en) * | 2018-05-15 | 2018-06-27 | Kancera Ab | New processes and products with increased chiral purity |
GB201811169D0 (en) * | 2018-07-06 | 2018-08-29 | Kancera Ab | New compounds |
GB202006849D0 (en) | 2020-05-08 | 2020-06-24 | Kancera Ab | New use |
WO2024083933A1 (en) | 2022-10-19 | 2024-04-25 | Astrazeneca Ab | 2,4,6-trisubstituted 1,3,5-triazines as modulators of cx 3cr1 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE543978A (es) | 1955-01-03 | |||
US4698327A (en) | 1985-04-25 | 1987-10-06 | Eli Lilly And Company | Novel glycopeptide derivatives |
US4639433A (en) | 1985-08-14 | 1987-01-27 | Eli Lilly And Company | Glycopeptide derivatives |
US4643987A (en) | 1985-08-14 | 1987-02-17 | Eli Lilly And Company | Modified glycopeptides |
IL96603A (en) | 1989-12-13 | 1998-02-08 | Lilly Co Eli | Antibacterial glycopeptide derivativesProcess for their preparation and pharmaceutical preparations containing the same |
US5202328A (en) | 1991-03-06 | 1993-04-13 | Merck & Co., Inc. | Substituted fused pyrimidinones |
US5840684A (en) | 1994-01-28 | 1998-11-24 | Eli Lilly And Company | Glycopeptide antibiotic derivatives |
EP1068212A1 (en) | 1998-04-03 | 2001-01-17 | Bristol-Myers Squibb Pharma Company | THIAZOLO 4,5-d]PYRIMIDINES AND PYRIDINES AS CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONISTS |
DE69936052T2 (de) | 1998-05-01 | 2008-01-17 | Eli Lilly And Co., Indianapolis | N1 modifizierte glycopeptide |
SE9802729D0 (sv) | 1998-08-13 | 1998-08-13 | Astra Pharma Prod | Novel Compounds |
SE9903544D0 (sv) * | 1999-10-01 | 1999-10-01 | Astra Pharma Prod | Novel compounds |
GB2359081A (en) * | 2000-02-11 | 2001-08-15 | Astrazeneca Uk Ltd | Pharmaceutically active thiazolopyrimidines |
ATE255584T1 (de) * | 2000-02-11 | 2003-12-15 | Astrazeneca Ab | Pyrimidinverbindungen und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität |
GB2359551A (en) | 2000-02-23 | 2001-08-29 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
SE0004110L (sv) | 2000-11-10 | 2002-05-11 | Forsheda Ab | Tätningsring |
SE0101082D0 (sv) | 2001-03-27 | 2001-03-27 | Astrazeneca Ab | Novel use |
SE0101322D0 (sv) | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | Novel compounds |
GB0221829D0 (en) | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
GB0221828D0 (en) | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
DK2526996T3 (da) * | 2002-12-20 | 2019-12-02 | Xeris Pharmaceuticals Inc | Formulering til intrakutan injektion |
AU2004278276B2 (en) | 2003-10-07 | 2007-10-18 | Astrazeneca Ab | New 2-substituted, 4-amino-thiazolo(4,5-d) pyrimidines, useful as chemokine receptor antagonists, esp. CX3CR1 |
US20090239882A1 (en) * | 2004-12-17 | 2009-09-24 | Astrazeneca Ab | Thiazolopyramidine Compounds for the Modulation of Chemokine Receptor Activity |
AR053347A1 (es) * | 2005-04-06 | 2007-05-02 | Astrazeneca Ab | Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos |
-
2006
- 2006-03-04 UA UAA200710491A patent/UA90707C2/ru unknown
- 2006-03-27 AR ARP060101169A patent/AR055890A1/es not_active Application Discontinuation
- 2006-03-28 TW TW095110726A patent/TW200714605A/zh unknown
- 2006-03-29 SA SA06270072A patent/SA06270072B1/ar unknown
- 2006-04-03 NZ NZ561460A patent/NZ561460A/en not_active IP Right Cessation
- 2006-04-03 PL PL06717078T patent/PL1869056T3/pl unknown
- 2006-04-03 RS RS20110006A patent/RS51581B/en unknown
- 2006-04-03 WO PCT/SE2006/000399 patent/WO2006107258A1/en active Application Filing
- 2006-04-03 MX MX2007012060A patent/MX2007012060A/es active IP Right Grant
- 2006-04-03 CA CA2604017A patent/CA2604017C/en not_active Expired - Fee Related
- 2006-04-03 ES ES06717078T patent/ES2354450T3/es active Active
- 2006-04-03 CN CN2006800200726A patent/CN101193897B/zh active Active
- 2006-04-03 AU AU2006231836A patent/AU2006231836B2/en not_active Ceased
- 2006-04-03 US US11/910,780 patent/US7947693B2/en active Active
- 2006-04-03 JP JP2008505262A patent/JP5165553B2/ja active Active
- 2006-04-03 DE DE602006018124T patent/DE602006018124D1/de active Active
- 2006-04-03 SI SI200630886T patent/SI1869056T1/sl unknown
- 2006-04-03 BR BRPI0609738-3A patent/BRPI0609738A2/pt not_active IP Right Cessation
- 2006-04-03 AT AT06717078T patent/ATE487727T1/de active
- 2006-04-03 PT PT06717078T patent/PT1869056E/pt unknown
- 2006-04-03 KR KR1020077022813A patent/KR101335055B1/ko not_active IP Right Cessation
- 2006-04-03 RU RU2007140551/04A patent/RU2419623C2/ru not_active IP Right Cessation
- 2006-04-03 EP EP06717078A patent/EP1869056B1/en active Active
- 2006-04-03 DK DK06717078.7T patent/DK1869056T3/da active
- 2006-04-04 UY UY29454A patent/UY29454A1/es not_active Application Discontinuation
-
2007
- 2007-09-11 IL IL185912A patent/IL185912A0/en unknown
- 2007-09-25 ZA ZA200708187A patent/ZA200708187B/xx unknown
- 2007-11-05 NO NO20075603A patent/NO20075603L/no not_active Application Discontinuation
-
2008
- 2008-11-14 HK HK08112536.8A patent/HK1118556A1/xx not_active IP Right Cessation
-
2010
- 2010-12-28 US US12/979,720 patent/US9440992B2/en active Active
-
2011
- 2011-01-13 CY CY20111100040T patent/CY1111316T1/el unknown
- 2011-01-21 HR HR20110047T patent/HRP20110047T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY29454A1 (es) | Derivados novedosos de 7-amino-(1,3) tiazol(4,5-d) pirimidina 5-sustituidos | |
CY1113798T1 (el) | Υποκατεστημενες ενωσεις διαζεπανης ως ανταγωνιστες υποδοχεα ορεξινης | |
UY29451A1 (es) | Derivados novedosos de (1,3)tiazolo(4,5-d)pirimidin-2-(3h)-ona 5,7-disustituida | |
CY1112255T1 (el) | Ενωσεις οι οποιες περιεχουν γουανιδινη που ειναι χρησιμες ως ανταγωνιστες του μουσκαρινικου υποδοχεα | |
CL2009000029A1 (es) | Compuestos heterocíclicos derivados de piridina sustituida; procedimiento de preparación de los compuestos; composición farmacéutica; su uso en el tratamiento de trastornos mediados por el receptor alk-5 o alk-4, útiles en el tratamiento de la hipertensión pulmonar, enfemedades renales, artritis, osteoporosis, entre otras. | |
BRPI0517945A (pt) | derivados de quinuclidina e seu uso como antagonistas de receptor muscarìnico m3 | |
GT200600013A (es) | Compuestos organicos | |
CL2012000981A1 (es) | Compuestos derivados de 5-etinil-2-[(3-fenil-1h-pirazolo[3.4-d]pirimidin-1-il)metil]quinazolin-4(3h)-ona, inhibidores de fosfoinositida 3-quinasa compuestos intermediarios; sin accion farmacologica; composicion farmaceutica; utiles en el tratamiento de epoc, asma fibrosis quistica y pulmonar, sarcoidosis, entre otras. | |
WO2008045393A3 (en) | Imidazo- and triazolo-pyridine compounds and methods of use therof | |
CO6321265A2 (es) | Compuestos de 2-amido-3-metil pirrolo pirimidinona fenilo -sustituidos como inhibidores bace-1 composiciones y su uso | |
ECSP088335A (es) | Compuestos de pirimidina amida como inhibidores de pgds | |
UY28720A1 (es) | Uso de pteridinas sustituidas para el tratamiento de enfermedades de la vías respiratorias | |
ATE440834T1 (de) | Substituierte arylaminderivate und verwendungsverfahren | |
CL2007003826A1 (es) | Compuestos derivados de n-(amino-(hetero)aril)-1h-pirrolopiridin-2-carboxamidas, antagonistas de receptores tipo trpv1; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como trastornos gastrointestinales, trastornos respiratorios, psoriasis y depresion. | |
CY1112370T1 (el) | Παραγωγα σουλφοναμιδης και χρηση αυτων στη ρυθμιση των μεταλλοπρωτεϊνασων | |
GT200500281A (es) | Compuestos organicos. | |
WO2008039139A8 (en) | Novel 5,7-disubstituted [1, 3] thiazolo [4, 5] pyrimidin-2 (3h)-amine derivatives and their use in therapy | |
UY31734A (es) | Nuevos derivados 258 5, 7-disustituidos de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona | |
EA200701758A1 (ru) | Замещённые арильные производные 1,4-пиразина | |
UY30612A1 (es) | Derivados 5,7 disustituidos de la [1,3]tiazolo[4,5,d]pirimidin-2(3h)-ona, proceso de preparacion y aplicaciones | |
EA200701348A1 (ru) | Сульфониламиноциклические соединения и их применение | |
NO20081483L (no) | Kombinasjon av forbindelser som kan brukes ved behandling av respiratoriske sykdommer, spesielt kronisk obstruktiv pulmonaer sykdom (COPD) og astma | |
NO20074458L (no) | N-hydroksamidderivater og anvendelse derav | |
BRPI0519788A2 (pt) | antagonistas do receptor 5-ht7 | |
NO20070820L (no) | Oktahydropyrrolo (2,3,C)pyridin-derivanter og farmasoytisk anvendelse derav. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20160810 |